Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 5/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9997232 | 0.89 | PFKFB3 (0.66) | PFKFB3MCL1GAAMEN1KMT2A | |
| SCHEMBL15056424 | 0.89 | PFKFB3 (0.60) | PFKFB3MCL1PLAUACLYSMN1; SMN2 | |
| SCHEMBL15056189 | 0.85 | PFKFB3 (0.57) | PFKFB3MCL1PLAUACLYALOX12 | |
| SCHEMBL19288127 | 0.84 | PFKFB3 (0.53) | PFKFB3MCL1PLAUACLYSMN1; SMN2 | |
| SCHEMBL9997101 | 0.84 | PFKFB3 (0.65) | PFKFB3MCL1PLAUGAALMNA | |
| SCHEMBL15055423 | 0.82 | PFKFB3 (0.51) | PFKFB3MCL1PLAUGAALMNA | |
| SCHEMBL15055770 | 0.82 | PFKFB3 (0.54) | PFKFB3MCL1PLAUSMN1; SMN2HSD17B2 | |
| SCHEMBL15080043 | 0.81 | PFKFB3 (0.79) | PFKFB3MCL1ACLYSMN1; SMN2HSD17B2 | |
| SCHEMBL15055056 | 0.80 | MAPT (0.55) | PFKFB3ACLYGAALMNAMAPT | |
| SCHEMBL16408071 | 0.80 | PFKFB3 (0.52) | PFKFB3MCL1PLAUSMN1; SMN2HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | claimed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | claimed |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2018-06-19 | — | — | US | claimed |
| EP-2794009-B1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2017-08-30 | — | — | EP | claimed |
| US-9718809-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2017-08-01 | — | — | US | claimed |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2016-08-04 | — | — | US | claimed |
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2015-01-22 | — | — | US | claimed |
| EP-2794009-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | Kancera AB (SE) | 2014-10-29 | — | — | EP | claimed |
| WO-2013093095-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2013-06-27 | — | — | WO | claimed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2018-06-19 | — | — | US | disclosed |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2018-06-19 | — | — | US | disclosed |
| EP-2794009-B1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2017-08-30 | — | — | EP | disclosed |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2016-08-04 | — | — | US | disclosed |
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2015-01-22 | — | — | US | disclosed |
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2015-01-22 | — | — | US | disclosed |
| EP-2794009-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | Kancera AB (SE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093095-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013093095-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | NFKBIA, IL6, LITAF | PFKFB3 909/4885MCL1 36/4885PLAU 3244/4885 |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | NFKBIA, IL6, LITAF | PFKFB3 988/4885MCL1 23/4885PLAU 3247/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | PFKFB3 1/4885MCL1 1411/4885PLAU 2025/4885 |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | NFKBIA, IL6, LITAF | PFKFB3 988/4885MCL1 23/4885PLAU 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.